Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPHINX spatial intratumoral drug distribution study in early ER-positive HER2-negative breast cancer
NL-OMON59576Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ribociclib in breast cancer (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Intratumoral concentration of aromatase inhibitor and ribociclib. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON59576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59576.